ResearcherUppsala UniversityActive in the last 2 years
Christopher Månsson
Matched on OpenAlex author ID A5013770210. Sources: OpenAlex.
Their work
- Papers
- 9
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 26
2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper
Papers 9
- R0 Resection improves survival after multivisceral resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2026.117352↗
- The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
- Prospective evaluation of surgical treatment of liver metastasizing pancreatic cancer - ScanPan study protocol. Co-author DOI 10.1186/s12893-025-02983-w↗
- Surveillance after surgery for pancreatic cancer: a global scoping review of guidelines and a nordic Survey of contemporary practice. Co-author DOI 10.1080/00365521.2024.2378948↗
- Ultrasound-guided Percutaneous Irreversible Electroporation for Treatment of Locally Recurrent Pancreatic Cancer After Surgical Resection. Co-author DOI 10.21873/anticanres.14249↗
- Percutaneous Irreversible Electroporation as First-line Treatment of Locally Advanced Pancreatic Cancer. Co-author DOI 10.21873/anticanres.13371↗
- The Value of CA19-9 After Irreversible Electroporation for Pancreatic Cancer. Co-author DOI 10.21873/anticanres.13827↗
- Percutaneous irreversible electroporation for treatment of locally advanced pancreatic cancer following chemotherapy or radiochemotherapy. Co-author DOI 10.1016/j.ejso.2016.01.024↗
- Safety and preliminary efficacy of ultrasound-guided percutaneous irreversible electroporation for treatment of localized pancreatic cancer. Co-author PMID 24403476↗
Closest collaborators
The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Britt‐Marie Karlson · 5 shared papers, 2014–2020 · strength 0.54
- Paper Ultrasound-guided Percutaneous Irreversible Electroporation for Treatment of Locally Recurrent Pancreatic Cancer After … DOI 10.21873/anticanres.14249↗
- Paper The Value of CA19-9 After Irreversible Electroporation for Pancreatic Cancer. DOI 10.21873/anticanres.13827↗
- Paper Percutaneous Irreversible Electroporation as First-line Treatment of Locally Advanced Pancreatic Cancer. DOI 10.21873/anticanres.13371↗
- Anders Nilsson · 5 shared papers, 2014–2020 · strength 0.54
- Paper Ultrasound-guided Percutaneous Irreversible Electroporation for Treatment of Locally Recurrent Pancreatic Cancer After … DOI 10.21873/anticanres.14249↗
- Paper The Value of CA19-9 After Irreversible Electroporation for Pancreatic Cancer. DOI 10.21873/anticanres.13827↗
- Paper Percutaneous Irreversible Electroporation as First-line Treatment of Locally Advanced Pancreatic Cancer. DOI 10.21873/anticanres.13371↗
- Bergþór Björnsson · 2 shared papers, 2024–2025 · strength 0.36
- Paper Prospective evaluation of surgical treatment of liver metastasizing pancreatic cancer - ScanPan study protocol. DOI 10.1186/s12893-025-02983-w↗
- Paper Surveillance after surgery for pancreatic cancer: a global scoping review of guidelines and a nordic Survey of contempo… DOI 10.1080/00365521.2024.2378948↗
- Asif Halimi · 2 shared papers, 2024–2025 · strength 0.36
- Paper Prospective evaluation of surgical treatment of liver metastasizing pancreatic cancer - ScanPan study protocol. DOI 10.1186/s12893-025-02983-w↗
- Paper Surveillance after surgery for pancreatic cancer: a global scoping review of guidelines and a nordic Survey of contempo… DOI 10.1080/00365521.2024.2378948↗
- Ernesto Sparrelid · 2 shared papers, 2024–2025 · strength 0.36
- Paper Prospective evaluation of surgical treatment of liver metastasizing pancreatic cancer - ScanPan study protocol. DOI 10.1186/s12893-025-02983-w↗
- Paper Surveillance after surgery for pancreatic cancer: a global scoping review of guidelines and a nordic Survey of contempo… DOI 10.1080/00365521.2024.2378948↗
- Nils O. Elander · 1 shared paper, 2025 · strength 0.20
- Kristina Hasselgren · 1 shared paper, 2025 · strength 0.20
- Heikki I. Huhta · 1 shared paper, 2025 · strength 0.20
- Poya Ghorbani · 1 shared paper, 2025 · strength 0.20
- Maria Gustafsson Liljefors · 1 shared paper, 2025 · strength 0.20
- Margareta Heby · 1 shared paper, 2025 · strength 0.20
- Daniel Öhlund · 1 shared paper, 2025 · strength 0.20
- Bodil Andersson · 1 shared paper, 2024 · strength 0.16
- Svein Olav Bratlie · 1 shared paper, 2024 · strength 0.16
- Hanna E. Seppänen · 1 shared paper, 2024 · strength 0.16
- Bobby Tingstedt · 1 shared paper, 2024 · strength 0.16
- Johanna Laukkarinen · 1 shared paper, 2024 · strength 0.16
- Linn Såve Nymo · 1 shared paper, 2024 · strength 0.16
- Jakob Kirkegård · 1 shared paper, 2024 · strength 0.16
- Roland E. Andersson · 1 shared paper, 2024 · strength 0.16
- Daniel Ansari · 1 shared paper, 2024 · strength 0.16
- Carsten Palnæs Hansen · 1 shared paper, 2024 · strength 0.16
- Knut Jørgen Labori · 1 shared paper, 2024 · strength 0.16
- Kjetil Søreide · 1 shared paper, 2024 · strength 0.16
- Saila P. Kauhanen · 1 shared paper, 2024 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.